Skip to content

US · PHVS · BIOTECHNOLOGY

Pharvaris N.V. (PHVS) intrinsic value and stock valuation

$31.28as of 2026-11-21 · Mkt cap 2.34B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Pharvaris N.V. DCF and intrinsic value

InvestorsCraft values PHVS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PHVS’s statements →

Pharvaris N.V. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Leiden, ZH 6300 pharvaris.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-175.7M
20182025
Free cash flow
-$-137.24M
20182025
Total equity
$271.3M+23.1% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-169.82M-$-145.69M-$-96.91M-$-86.71M-$-54.14M
Net income-$-175.7M-$-134.22M-$-100.88M-$-76.33M-$-42.73M
EPSd-$-2.97M-$-2.48M-$-2.63M-$-2.27M-$-1.41M
Operating cash flow-$-137.07M-$-120.13M-$-93.05M-$-67.16M-$-44.6M
Capital expenditure-$-160K-$-540K-$-90K-$-120K-$-130K
Free cash flow-$-137.24M-$-120.67M-$-93.14M-$-67.29M-$-44.73M
Total assets$301.5M$291.4M$398.7M$167.7M$212.1M
Total debt$780K$860K$240K$440K$250K
Net debt-$-290.9M-$-279.87M-$-390.99M-$-161.4M-$-209.1M
Total equity$271.3M$267.8M$384.1M$149.3M$205M
Cash and short-term investments$291.7M$280.7M$391.2M$161.8M$209.4M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$124.5M$98.6M$65.6M$57.4M$35.8M
Selling, general and administrative expenses$45.3M$47.1M$31.3M$29.3M$18.4M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$169.8M$145.7M$96.9M$86.7M$54.1M
Cost and expenses$169.8M$145.7M$96.9M$86.7M$54.1M
Interest income$0.00$5.47M$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$20K$280K
Depreciation and amortization$420K$100K$260K$150K$80K
Ebitda-$-173.29M-$-145.59M-$-99.57M-$-86.56M-$-42.31M
Operating income-$-169.82M-$-145.69M-$-96.91M-$-86.71M-$-54.14M
Total other income/expenses, net-$-3.89M$13.3M-$-2.91M$11.1M$11.5M
Income before tax-$-173.71M-$-132.4M-$-99.83M-$-75.65M-$-42.66M
Income tax expense$1.99M$1.83M$1.05M$680K$70K
Net income-$-175.7M-$-134.22M-$-100.88M-$-76.33M-$-42.73M
Weighted average shares outstanding$59.2M$54M$38.4M$33.6M$30.4M
Weighted average diluted shares outstanding$59.2M$54M$38.4M$33.6M$30.4M
Balance sheet
20252024202320222021
Cash and short-term investments$291.7M$280.7M$391.2M$161.8M$209.4M
Net receivables$4.55M$2.94M$1.04M$380K$700K
Inventory$0.00$0.00$0.00$4.04M$0.00
Total current assets$299.2M$289.4M$397.9M$166.9M$211.6M
Property, plant and equipment, net$1.4M$1.48M$460K$630K$350K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.29M$1.96M$840K$890K$520K
Total assets$301.5M$291.4M$398.7M$167.7M$212.1M
Accounts payable$5.11M$4.56M$2.91M$5.98M$2.13M
Short-term debt$200K$220K$200K$190K$100K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$29.6M$23M$14.6M$18.2M$6.99M
Long-term debt$580K$640K$40K$250K$150K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$580K$640K$40K$250K$150K
Capital lease obligations$780K$860K$240K$440K$250K
Total liabilities$30.2M$23.6M$14.7M$18.5M$7.14M
Common stock$7.83M$6.53M$6.27M$4.06M$3.98M
Retained earnings-$-579.6M-$-402.26M-$-265.92M-$-164.19M-$-87.57M
Accumulated other comprehensive income (loss)$50.5M$39.9M$27.9M$20.2M$9.8M
Total equity$271.3M$267.8M$384.1M$149.3M$205M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$780K$860K$240K$440K$250K
Net debt-$-290.9M-$-279.87M-$-390.99M-$-161.4M-$-209.1M
Cash flow statement
20252024202320222021
Net income-$-173.71M-$-132.4M-$-99.83M-$-75.65M-$-42.66M
Depreciation and amortization$420K$270K$260K$150K$80K
Stock-based compensation$19.1M$16.2M$10.7M$11.4M$8.2M
Change in working capital$7.62M$5.89M-$-5.86M$8.38M$1.58M
Accounts receivable-$-330K-$-30K-$-40K$320K-$-130K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-137.07M-$-120.13M-$-93.05M-$-67.16M-$-44.6M
Investments in property, plant and equipment-$-160K-$-540K-$-90K-$-120K-$-130K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-160K-$-540K-$-90K-$-120K-$-130K
Common stock issued$171.7M$2.24M$342.9M$9.61M$156.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$160.6M$2.68M$325.4M$8.65M$143.7M
Net change in cash$11M-$-110.5M$229.4M-$-47.52M$110.7M
Cash at end of period$291.7M$280.7M$391.2M$161.8M$209.4M
Operating cash flow-$-137.07M-$-120.13M-$-93.05M-$-67.16M-$-44.6M
Capital expenditure-$-160K-$-540K-$-90K-$-120K-$-130K
Free cash flow-$-137.24M-$-120.67M-$-93.14M-$-67.29M-$-44.73M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Pharvaris N.V.

        Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

        CEO
        Berndt Modig
        Employees
        134
        Beta
        -2.34

        Explore

        Frequently asked questions

        What is the intrinsic value of Pharvaris N.V. (PHVS)?

        InvestorsCraft does not currently publish an intrinsic value for PHVS. How the IC value is calculated.

        Is PHVS undervalued?

        InvestorsCraft does not publish an undervaluation signal for PHVS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.